Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-01-03 |
2023-09 |
0 |
N/A |
N/A |
N/A |
2023-10-03 |
2023-06 |
0 |
N/A |
N/A |
N/A |
2023-07-04 |
2023-03 |
0 |
N/A |
N/A |
N/A |
2023-03-31 |
2022-12 |
0 |
N/A |
N/A |
N/A |
2022-11-09 |
2022-09 |
-0.42 |
N/A |
N/A |
N/A |
2022-08-09 |
2022-06 |
-0.52 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-09-13 |
Guggenheim |
Downgrade |
Buy |
Neutral |
2022-09-09 |
Morgan Stanley |
Upgrade |
|
Equal-Weight |
2022-08-09 |
SVB Leerink |
Upgrade |
|
Market Perform |
2022-05-11 |
Morgan Stanley |
Upgrade |
|
Equal-Weight |
2022-05-11 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-05-10 |
SVB Leerink |
Upgrade |
|
Market Perform |
Date |
Name |
Relation |
Quantity |
Description |
2023-02-23 |
APPELHANS DANNIELLE |
Chief Executive Officer |
0.00 |
Sale |
2023-01-31 |
CAGNONI PABLO J |
Director |
66.08K |
Sale |
2019-12-15 |
CARPENTER CHRISTOPHER L |
Officer |
34.84K |
Sale |
2020-04-21 |
COUGHLIN CHRISTINA M M.D., PH.D. |
Officer |
19.00K |
Purchase |
2022-04-20 |
EPSTEIN DAVID R |
Director |
4.72M |
Purchase |
2021-03-18 |
FLAGSHIP VENTURES FUND IV GENERAL PARTNER L L C |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-12-30 |
Flagship Pioneering Inc. |
38.51M |
3.20M |
42.60% |
2022-12-30 |
FMR, LLC |
12.38M |
1.03M |
13.69% |
2022-12-30 |
Baillie Gifford and Company |
4.87M |
404.14K |
5.39% |
2022-12-30 |
Artal Group S.A. |
2.04M |
169.54K |
2.26% |
2022-12-30 |
Vanguard Group, Inc. (The) |
1.68M |
139.16K |
1.85% |
2022-12-30 |
Acadian Asset Management. LLC |
1.28M |
106.01K |
1.41% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-11-29 |
Fidelity Growth Company Fund |
4.39M |
364.29K |
4.86% |
2022-11-29 |
Fidelity Growth Company K6 Fund |
1.34M |
110.91K |
1.48% |
2022-11-29 |
Fidelity Series Growth Company Fund |
1.11M |
91.91K |
1.23% |
2022-09-29 |
Vanguard Total Stock Market Index Fund |
1.07M |
88.55K |
1.18% |
2022-09-29 |
Vanguard Extended Market Index Fund |
553.39K |
45.93K |
0.61% |
2022-11-29 |
Fidelity Extended Market Index Fund |
225.43K |
18.71K |
0.25% |